|
|
|
|
Epidemiology of lumbar osteoporosis and osteoarthritis and their causal relationship--is osteoarthritis a pred
The cumulative incidence of lumbar OA over 10 yrs aged 4079 yrs was 25.8% in men and 45.Epidemiology of lumbar osteoporosis and osteoarthritis and their causal relationship--is osteoarthritis a pred.
|
|
|
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Tre
TAMPA, Fla., Nov.3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding...
|
|
|
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Tre
TAMPA, Fla., Nov.3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding...
|
|
|
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Tre
TAMPA, Fla., Nov.3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding...
|
|
|
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Tre
TAMPA, Fla., Nov.3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding...
|
|
|
Durezol in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatme
/PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding eye diseases will be...
|
|
|
Durezol in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatme
/PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding eye diseases will be...
|
|
|
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
- Reaffirms 2008 Revenue Guidance of $75 to $82 million - IRVINE, Calif., Oct.30 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today reported financial results for the third...
|
|
|
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
- Reaffirms 2008 Revenue Guidance of $75 to $82 million - IRVINE, Calif., Oct.30 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today reported financial results for the third...
|
|
|
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
- Reaffirms 2008 Revenue Guidance of $75 to $82 million - IRVINE, Calif., Oct.30 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today reported financial results for the third...
|
|
|
Management of Retinitis Pigmentosa
ELIOT L.BERSON, MD Retinitis pigmentosa (RP) has a prevalence of about 1 in 4000; an estimated 2 million people are affected worldwide. The condition is most often inherited by an autosomal dominant, autosomal recessive, or X-linked...
|
|
|
Study shows steroid therapies following transplant can be eliminated
CINCINNATIA new study by researchers at the (UC) shows that using modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a transplant surgery while still maintaining kidney function.Steve...
|
|
|
Eastern Biotech to promote deCODE Genetics' DNA-based tests for assessing risk of diabetes and other pred
Eastern Biotech of Dubai has announced its partnership with deCODE Genetics to market deCODEs tests for genetic variants conferring risk of a number of common diseases.The partnership allows Eastern Biotech to offer its clients access to...
|
|
|
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
Normal Version TAMPA, Fla., Oct.14 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today preliminary results from a pivotal anterior uveitis trial that compared Durezol...
|
|
|
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol
/PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today preliminary results from a pivotal anterior uveitis trial that compared Durezol(TM) (difluprednate ophthalmic emulsion)...
|
|
|
Shop For The Cure: Buy a pretty pink RuMe Reuseable Bag, donate to Breast Cancer Action 1 day
The process is simple - purchase a pink RuMe Reusable Bag from Delight.com and $2 from each purchase willbe donated to Breast Cancer Action.Add on an adorable pink Klean Kanteen reusable water bottle, and an additional $1 will be added to...
|
|
|
Shop For The Cure: Buy a Pretty Pink RuMe ReUseable Bag donate to Breat Cancer Action 16 hrs
The process is simple - purchase a pink RuMe Reusable Bag from Delight.com and $2 from each purchase willbe donated to Breast Cancer Action.Add on an adorable pink Klean Kanteen reusable water bottle, and an additional $1 will be added to...
|
|
|
ISTA Pharmaceuticals Receives $65 Million Funding Commitment
Funding Led by Deerfield Management with Co-investors Sprout and Sanderling Ventures ISTA Redeems $40 Million Outstanding Convertible Bonds IRVINE, Calif., Sept.26 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA -...
|
|
|
ISTA Pharmaceuticals Receives $65 Million Funding Commitment
Funding Led by Deerfield Management with Co-investors Sprout and Sanderling Ventures IRVINE, Calif., Sept.26 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it has entered into an agreement with its long-term...
|
|
|
ISTA Pharmaceuticals Receives $65 Million Funding Commitment
IRVINE, Calif., Sept.26 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it has entered into an agreement with its long-term shareholders, Deerfield Management, Sprout and Sanderling Ventures to provide ISTA with...
|
